Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s238. https://doi.org/10.25251/skin.7.supp.238